<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

XL 388

產(chǎn)品貨號

Axon 2951 CAS [1251156-08-7] MF C23H22FN3O4SMW 455.50 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Recently added

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

XL 388

Based on 5 reference(s) in Google Scholar 8 10 5

Axon 2951

CAS [1251156-08-7]

MF C23H22FN3O4S
MW 455.50

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

Recently added

XL 388

Description

Highly potent, selective, ATP-competitive, and orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with an IC50 value of 9.9 nM. Moreover, XL 388 is an mTORC1/2 dual inhibitor which displayed good pharmacokinetics and oral exposure in multiple species with moderate bioavailability. XL 388 showed anti-cancer activity in preclinical osteosarcoma models and inhibited survival and proliferation of RCC cell lines and primary human RCC cells.

CS Takeuchi et al. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR). J Med Chem. 2013 Mar 28;56(6):2218-34.

YR Zhu et al. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models. Oncotarget. 2016 Aug 2;7(31):49527-49538.

Z Xiong et al. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent. Oncotarget. 2017 May 2;8(18):30151-30161.

Certificate of Analysis
Material Safety Data Sheet

Apoptosis Cell Signaling & Oncology mTOR PI3K-Akt-mTOR EC 2.7.11.1

Highly potent, selective, ATP-competitive, and orally bioavailable mTOR inhibitor

Chemical name

(7-(6-Aminopyridin-3-yl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)(3-fluoro-2-methyl-4-(methylsulfonyl)phenyl)methanone

Parent CAS No.

[1251156-08-7]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>